Cancer antigen 125: A sensitive marker of ascites in patients with liver cirrhosis

American Journal of Gastroenterology

Volumn 94, Issue 6, 1999, Pages 1613-1618

  Zuckerman, Eli ^a   Lanir, Amos ^a   Sabo, Edmund ^a   Rosenvald Zuckerman, Tsila ^b   Matter, Ibrahim ^a   Yeshurun, Daniel ^a   Eldar, Samuel ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCITES; CHRONIC LIVER DISEASE; CONTROLLED STUDY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; OVARY CANCER; PARACENTESIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; BIOLOGICAL MARKERS; CA-125 ANTIGEN; CHRONIC DISEASE; HUMANS; LIVER CIRRHOSIS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 0033014416     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01152.x     Document Type: Article

References (29)

1. Bast R.C. Jr, Feeney M., Lazarus M., et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 68:1981;1331-1337.
2. Bast R.C. Jr, Klug T.L., St. John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:1983;883-887.
3. Ozasa H., Noda Y., Mori T. Progesterone increases serum CA 125 in endometriosis. Fertil Steril. 47:1987;699-701.
4. Halila H., Stenman U.H., Seppala M. Ovarian cancer antigen CA 125 in pelvic inflammatory disease and pregnancy. Cancer. 57:1986;1327-1329.
5. Jager W., Diedrich K., Wildt L. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil Steril. 47:1987;675-678.
6. Young R.C., Knapp R.C., Perez C.A. Cancer of the ovary. De Vita V.T. Jr, Hellman S., Rosenberg S.A. Cancer Principles and practice of oncology . 1982;884-913 JB Lippincott, Philadelphia.
7. Niloff J.M., Klug T.L., Schaetzl E., et al. Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium and endocervix. Am J Obstet Gynecol. 148:1984;1057-1058.
8. Ruibal A, Encabo G, Mirrales EM, et al. CA 125 seric levels in human clinical practice. Our experience in 1542 cases (Poster). International Meeting on Monoclonal antibodies in Oncology: Clinical applications. Nantes, France, June 1985.
9. Molina R., Filella X., Bruix J., et al. Cancer antigen CA 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 37:1991;1379-1383.
10. Ruibal A., Encabo G., Martinez-Miralles E., et al. CA 125 seric levels in nonmalignant pathologies. Bull Cancer. 71:1984;145-146. (letter).
11. Molina R., Ballesta A.M., Casals E., et al. Value of CA 125 antigen as tumor marker Preliminary results . Protides Biol Fluids. 32:1985;613-617.
12. Ricolleau G., Chatal J.F., Fumoleau P., et al. Radioimmunoassay of the CA 125 antigen in ovarian carcinoma. Advantages compared with CA 19.9 and CEA. Tumor Biol. 5:1984;151-159.
13. Bergmann J.F., Beaugrand M., Labadie H., et al. CA 125 (ovarian tumor-associated antigen) in ascitic liver diseases. Clin Chim Acta. 155:1986;163-165.
14. Bergmann J.F., Bidart J.M., George M., et al. Elevation of CA-125 in patients with benign and malignant ascites. Cancer. 59:1987;213-217.
15. Mezger J., Wilmanns W., Lamerz R. Elevated serum CA-125 levels in patients with benign ascitic or pleural effusions. Tumor Biol. 9:1988;47-52.
16. Collazos J., Genolla J., Allende M.T., et al. Serum CA 125 levels in patients with non-malignant liver diseases without ascites. Clin Invest. 71:1993;239.
17. Haglund C., Kuusela P., Roberts P., et al. Tumor marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest. 51:1991;265-270.
18. Collazos J., Genolla J., Ruibal A. CA 125 levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. Scan J Clin Lab Invest. 52:1992;201-206.
19. Daoud E., Bodor G., Weaver C., et al. CA-125 concentrations in malignant and nonmalignant disease (Washington University Case Conference). Clin Chem. 37:1991;1968-1974.
20. Dubbins PA. The peritoneum. In: Cosgrove D, Meire H, Dewbury K., eds. Clinical ultrasound, abdominal and general ultrasound, 1st ed. London: Churchill Livingstone, 1993:737-42.
21. Forsby J., Henriksson L. Detectability of intraperitoneal fluid by ultrasonography. Acta Radiol Diag. 25:1984;375.
22. Dubbins PA. The peritoneum. In: Cosgrove D, Meire H, Dewbury K, eds. Clinical ultrasound, abdominal and general ultrasound, 1st ed. London: Churchill Livingstone, 1993;743-50.
23. Eerdekens M.W., Nouwen E.J., Pollet D.E., et al. Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases. Clin Chem. 31:1985;687-690.
24. Ruibal A., Siurana R. Evidence of a relationship between high serum CA 125 and liver failure pattern in cirrhotic patients without ascites and jaundice. Int J Biol Markers. 1:1986;55-56.
25. Kabawat S.E., Bast R.C., Bhan A.K., et al. Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 2:1984;275-285.
26. Mezger J., Lamerz R., Arnholdt H., et al. Tumor-marker in der diagnostik von aszites- und pleura-punktaten. Onkologie. 9:1986;11-16.
27. Jacobs I., Bast R.C. Jr. The CA 125 tumor-associated antigen A review of the literature . Hum Reprod. 4:1989;1-12.
28. Collazos J., Genolla J., Allende M.T., et al. Serum CA 125 levels in patients with non-malignant liver diseases without ascites. Clin Invest. 71:1993;239.
29. Zuckerman E., Qian D.J. CA-125 is a highly sensitive marker for diagnosis and monitoring of ascites in cirrhotic patients. Hepatology. 24:1996;604A. (abstract).